Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Orchestra Biomed
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of their collaboration agreement, Orchestra BioMed and Terumo plan to execute a global clinical program Virtue SAB (sirolimus), in an effort to gain regulatory approval for commercial sale of Virtue SAB in multiple markets and indications...
Product Name : Virtue SAB
Product Type : Antibiotic
Upfront Cash : $30.0 million
July 05, 2022
Lead Product(s) : Sirolimus
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Orchestra Biomed
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Nitrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Recipient : Inha University
Deal Size : Inapplicable
Deal Type : Inapplicable
Effect of Ultimaster Stents Treated to the Most Dilated Coronary Vessels
Details : Nitrate is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Coronary Artery Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 18, 2021
Lead Product(s) : Nitrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Recipient : Inha University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cangrelor
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Recipient : University Hospital, Caen
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cangrelor is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of ST Elevation Myocardial Infarction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 16, 2021
Lead Product(s) : Cangrelor
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Recipient : University Hospital, Caen
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Platelet Rich Plasma
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Undisclosed
Recipient : University of Colorado, Denver
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Platelet Rich Plasma is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Osteochondritis Dissecans.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 24, 2015
Lead Product(s) : Platelet Rich Plasma
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Undisclosed
Recipient : University of Colorado, Denver
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Granulocyte Colony Stimulating Factor
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Evaluation of the Spectra Optia CMNC Collection Procedure
Details : Granulocyte Colony Stimulating Factor is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 01, 2014
Lead Product(s) : Granulocyte Colony Stimulating Factor
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
